Shares of UiPath Inc. (NYSE:PATH – Get Free Report) have received a consensus rating of “Moderate Buy” from the eighteen analysts that are currently covering the stock, Marketbeat.com reports. Nine equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $27.41.
A number of research analysts have recently weighed in on PATH shares. DA Davidson raised their price objective on UiPath from $20.00 to $24.00 and gave the company a “neutral” rating in a research report on Thursday, March 14th. JPMorgan Chase & Co. upgraded UiPath from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $22.00 to $28.00 in a research report on Thursday, March 14th. Evercore ISI raised their price objective on UiPath from $24.00 to $27.00 and gave the company an “in-line” rating in a research report on Thursday, March 14th. Bank of America boosted their price objective on UiPath from $26.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 14th. Finally, BMO Capital Markets raised their price objective on UiPath from $24.00 to $28.00 and gave the company a “market perform” rating in a research note on Thursday, March 14th.
View Our Latest Report on UiPath
Insider Buying and Selling at UiPath
Hedge Funds Weigh In On UiPath
A number of hedge funds and other institutional investors have recently made changes to their positions in PATH. Mark Sheptoff Financial Planning LLC purchased a new stake in UiPath in the fourth quarter worth about $25,000. HighMark Wealth Management LLC bought a new position in shares of UiPath during the fourth quarter valued at approximately $27,000. ORG Partners LLC boosted its stake in shares of UiPath by 875.6% during the first quarter. ORG Partners LLC now owns 1,239 shares of the healthcare company’s stock valued at $27,000 after purchasing an additional 1,112 shares in the last quarter. Cypress Capital Management LLC WY bought a new position in shares of UiPath during the fourth quarter valued at approximately $29,000. Finally, Fifth Third Bancorp boosted its stake in shares of UiPath by 2,005.3% during the third quarter. Fifth Third Bancorp now owns 2,000 shares of the healthcare company’s stock valued at $34,000 after purchasing an additional 1,905 shares in the last quarter. Institutional investors own 62.50% of the company’s stock.
UiPath Stock Up 1.8 %
NYSE:PATH opened at $19.84 on Friday. The business’s 50-day simple moving average is $21.75 and its two-hundred day simple moving average is $21.72. The stock has a market cap of $11.29 billion, a PE ratio of -116.40 and a beta of 1.01. UiPath has a 52 week low of $12.89 and a 52 week high of $27.87.
UiPath (NYSE:PATH – Get Free Report) last posted its quarterly earnings results on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.10. The business had revenue of $405.25 million for the quarter, compared to analysts’ expectations of $383.32 million. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. Sell-side analysts anticipate that UiPath will post -0.04 earnings per share for the current fiscal year.
UiPath Company Profile
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.
Read More
- Five stocks we like better than UiPath
- What does consumer price index measure?
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 3 Value Stocks You Can Buy Before They Become Big
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Chinese Stocks Stage Impressive Rebound
Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.